Form 4: Predictive Oncology Director Receives RSU Grant

Predictive Oncology Inc. Director Matthew Hawryluk was granted 64,680 restricted stock units, vesting fully on October 31, 2025.

Summary

• Matthew Hawryluk, a Director of Predictive Oncology Inc. (POAI), was granted 64,680 Restricted Stock Units (RSUs) on September 9, 2025.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs will vest in full on October 31, 2025, contingent on his continued service to the company.
• Following this transaction, Mr. Hawryluk beneficially owns 74,168 shares directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event that aligns director interests with shareholders, but doesn't indicate new operational performance or strategic shifts.

Positives

• The grant of RSUs aligns the director's interests with long-term shareholder value, as vesting is contingent on continued service and future stock performance.
• It serves as a retention incentive for key management personnel.

Negatives

• The grant of RSUs, while common, represents potential minor dilution for existing shareholders upon vesting.

Future Outlook

The vesting of the RSUs on October 31, 2025, is contingent on the director's continued service, indicating an expectation of ongoing commitment from key personnel.

Industry Context

Equity grants like RSUs are a standard component of executive and director compensation packages across various industries, particularly in biotechnology and technology sectors, to align management incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The grant of RSUs to a director is a common practice in public companies, comparable to compensation structures seen at other small-cap biotech firms.
• While specific comparable companies or projects are not detailed, such grants are generally benchmarked against peer groups to ensure competitive compensation and retention.

Related Party Transactions

• Grant of 64,680 Restricted Stock Units (RSUs) to Matthew Hawryluk, a Director of Predictive Oncology Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but also improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The RSUs are scheduled to vest in full on October 31, 2025, subject to Matthew Hawryluk's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director as part of their compensation, which is a standard practice to align interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on prior analysis of the company's fundamentals.

Keywords

Predictive Oncology, POAI, Form 4, Restricted Stock Units, RSU, Insider Ownership, Director Compensation, Equity Grant, Beneficial Ownership